The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery

The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery

(1) Background: The intravesical instillation of interleukin-2 (IL-2) has been shown to be very well tolerated and promising in patients with bladder malignancies. This study aims to confirm the use of a new IL-2 containing immunotherapy candidate as safe for intravesical application. IL-2, produced...

Full description

Bibliographic Details
Main Authors: Lisa Schmitz, Belinda Berdien, Edith Huland, Petra Dase, Karin Beutel, Margit Fisch, Oliver Engel
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Life
Subjects:
interleukin-2
urothelial cells
intravesical
immunotherapy
bladder cancer
Online Access:https://www.mdpi.com/2075-1729/10/10/231

Internet

https://www.mdpi.com/2075-1729/10/10/231

Similar Items